546 related articles for article (PubMed ID: 30321909)
1. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
2. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification.
Turkoz I; Sobel M; Alphs L
Pharm Stat; 2019 Jan; 18(1):22-38. PubMed ID: 30221459
[TBL] [Abstract][Full Text] [Related]
3. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.
Jin Y; Smith C; Monteith D; Brown R; Camporeale A; McNearney TA; Deeg MA; Raddad E; Xiao N; de la Peña A; Kivitz AJ; Schnitzer TJ
Osteoarthritis Cartilage; 2018 Dec; 26(12):1609-1618. PubMed ID: 30240937
[TBL] [Abstract][Full Text] [Related]
4. Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
Lesaffre E; Edelman MJ; Hanna NH; Park K; Thatcher N; Willemsen S; Gaschler-Markefski B; Kaiser R; Manegold C
Ann Oncol; 2017 Jul; 28(7):1419-1426. PubMed ID: 28184431
[TBL] [Abstract][Full Text] [Related]
5. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.
Asano J; Hirakawa A
Pharm Stat; 2020 Nov; 19(6):975-1000. PubMed ID: 32779393
[TBL] [Abstract][Full Text] [Related]
8. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
9. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
10. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
Ohwada S; Morita S
Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
[TBL] [Abstract][Full Text] [Related]
11. Comparing Bayesian early stopping boundaries for phase II clinical trials.
Jiang L; Yan F; Thall PF; Huang X
Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
[TBL] [Abstract][Full Text] [Related]
12. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
14. Information time scales for interim analyses of randomized clinical trials.
Freidlin B; Othus M; Korn EL
Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
[TBL] [Abstract][Full Text] [Related]
15. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
16. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
Shan G; Ma C; Hutson AD; Wilding GE
J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
18. Optimal timing for an accelerated interim futility analysis incorporating real world data.
Haine LMF; Murray TA; Koopmeiners JS
Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
[TBL] [Abstract][Full Text] [Related]
19. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
Rufibach K; Heinzmann D; Monnet A
Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
[TBL] [Abstract][Full Text] [Related]
20. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
Sharma P; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]